Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07039916 | Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis | PHASE3 | RECRUITING | 231 | — | — | May 27, 2025 | Dec 1, 2028 | May 22, 2026 | 83 | United States, Argentina +12 |
| Arm | Type | Description |
|---|---|---|
| Group 1: IMVT-1402 Dose 1 | EXPERIMENTAL | - |
| Group 2: IMVT-1402 Dose 2 | EXPERIMENTAL | - |
| Placebo/ IMVT-1402 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| IMVT-1402 | DRUG | • Dose 1 subcutaneous (SC) once weekly (QW) for 12 weeks (Period 1) |
| Placebo | DRUG | • Placebo SC QW for 12 weeks (Period 1) |
Inclusion Criteria: * Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures. * Have mild to severe gMG by Myasthenia Gravis Foundation of America (MGFA) classification of Class II, III, or IVa at th...